SCHEMBL4365965

SCHEMBL4365965

CC1(C)CCC(C)(C)c2cc(CCO)ccc21

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP26B1 Q9NR63 8/20 0.55
CYP26A1 O43174 7/20 0.55
RXRA P19793 6/20 0.54
RXRB P28702 3/20 0.54
RXRG P48443 3/20 0.54
RARB P10826 4/20 0.49
RARG P13631 4/20 0.49
RARA P10276 3/20 0.49
CYP3A4 P08684 1/20 0.45
PPARG P37231 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX5 P09917 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
BACE1 P56817 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4668411 0.89 CYP26B1 (0.52) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL2095481 0.85 RXRA (0.57) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL2897524 0.83 CYP26B1 (0.53) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL11949124 0.82 KDM4E (0.40) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL16998630 0.81 CYP26B1 (0.51) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL11240978 0.81 CYP26B1 (0.51) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL6909472 0.80 CYP26B1 (0.50) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL21776768 0.80 CYP26B1 (0.83) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL9075009 0.80 RXRA (0.39) CYP26B1CYP26A1RXRARXRBRXRG
SCHEMBL7142134 0.79 CYP26B1 (0.49) CYP26B1CYP26A1RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061760-A1 BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2009-05-27 EP disclosed
EP-1924546-A1 CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS Amgen, Inc (US) 2008-05-28 EP disclosed
WO-2008030618-A1 BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2008-03-13 WO disclosed
WO-2007033002-A1 CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2007-03-22 WO disclosed
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB CYP26B1 923/4885CYP26A1 474/4885RXRA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.